Stenocare has entered into an agreement to acquire all shares in Canngros from DanCann. The deal is expected to add annual revenues of approximately DKK 4-6 million, propelling the company towards it’s break even goal. BioStock contacted CEO Thomas Skovlund Schnegelsberg to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/stenocare-forvarvar-canngros/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
© Modular Finance, source Nordic Press Releases